
Granza Bio
Granza Bio is a YC Winter 2024 (W24) company. Based in San Francisco, CA, USA. Team of 7.
About Granza Bio
Summary
Granza Bio develops cancer and immune-disease therapeutics built on a cytotoxic mechanism called supramolecular attack particles, autonomous killing entities released by cytotoxic immune cells. The biology, discovered in co-founder Prof. Dustin's Oxford lab and published in Science in 2020, enables a new class of targeted medicines that harness the immune system's own killing machinery. The work it replaces is conventional immune-cell therapy approaches that lack this persistent, target-directed killing capability.
From the Y Combinator listing
Reprogramming Immunity for Target-Specific Medicines
Granza Bio is building on the discovery of a previously unknown cytotoxic mechanism in T cells: supramolecular attack particles (SMAPs, Science 2020). This biology reveals a new modality through which cytotoxic lymphocytes deliver persistent, high-intensity killing.
Facts
- Healthcare / Healthcare -> Therapeutics
- San Francisco, CA, USA
- 7
- Active
- Early
Founders (2)
- Ashwin Jainarayanan
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works